Company profile
Xilio Therapeutics, Inc.
NASDAQ:XLOBiotechnology: Pharmaceutical Preparations
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04896697 | phase1_2 | completed | 2021-09-13 | 2026-05-18 | Xilio Development, Inc. | Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors |
| NCT05052268 | phase1_2 | completed | 2022-01-18 | 2025-03-22 | Xilio Development, Inc. | XTX202 in Patients With Advanced Solid Tumors |
| NCT05684965 | phase1_2 | recruiting | 2023-05-11 | 2028-09-01 | Xilio Development, Inc. | XTX301 in Patients With Advanced Solid Tumors |
| NCT07688577 | phase1_2 | not_yet_recruiting | 2026-08-01 | 2029-11-01 | Xilio Development, Inc. | XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors |
FDA applications (0)
No records yet.